GSTM1 and anemia: A more conservative ruxolitinib dosing regimen (10 mg twice daily for the first 12 weeks, followed by dose escalation as tolerated) was administered to MF patients with anemia (Hb < 10 g/dL) in a phase 2 single-arm study (REALISE trial) [36].